Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLLLydia Scarfò, Paolo Ghia, Marta Coscia et al.|Blood|2022Cited by 10
P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORTLydia Scarfò, Paolo Ghia, Silvia Heltai et al.|HemaSphere|2023Cited by 2
Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve StudyElisabetta Albi, Paolo Ghia, Lydia Scarfò et al.|Blood|2023Cited by 2
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Lara Crucitti, Andrea Galitzia et al.|Haematologica|2025Cited by 2
Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and TolerabilityAlessandra Tedeschi, Luca Laurenti, Andrea Galitzia et al.|Blood|2023Cited by 1